March 27 (Reuters) – Hong Kong expects the preliminary findings of an investigation into packaging defects of the COVID-19 vaccine developed by Germany’s BioNTech SE as quickly as subsequent week, the South China Morning Submit reported on Saturday, citing Secretary for the Civil Service Patrick Nip (https://bit.ly/3w3c1ZN).
Nip stated he had personally requested senior administration of China’s Fosun Pharma to ship a brand new batch of the vaccines to Hong Kong if there have been security considerations with the prevailing ones, the SCMP reported.
The BioNTech vaccine is distributed in Hong Kong and Macau by way of a partnership with Fosun Pharma. BioNTech companions with Pfizer Inc in markets exterior better China.
BioNTech stated on March 24 it had determined to pause additional vaccination with the batch till the investigation is full as a precautionary measure and that no different batches shipped to different areas are affected by this investigation.
Individuals are anticipated to get their booster dose earlier than mid-April, Nip stated on a radio present, in keeping with the SCMP report. “We’ll give precedence to those that want the second dose after we assign the brand new time slots and venues as soon as the vaccinations with BioNTech can resume,” the report added.
Hong Kong and Macau halted using a COVID-19 vaccine developed by BioNTech on Wednesday, citing faulty packaging, in a transfer that triggered scenes of confusion in inoculation centres throughout the town.
(Reporting by Anirudh Saligrama in Bengaluru Enhancing by Shri Navaratnam)